Comparison of ovarian response in the same women with the same or different lots of human menopausal gonadotropin

M. P. Diamond, M. L. Polar, M. Blanchette, C. M. Mazure, A. H. Dechemey, B. Lunenfeld

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A variation in the bioactivity of different production lots of human menopausal gonadotropin (hMG) has been suggested. Therefore, we evaluated ovarian response to hMG in 14 women during three separate IVF cycles. The first two cycles were performed with the same lot (-03310027; Cycles A1 and A2); the third cycle utilized different lots of hMG (Cycle B). In all cycles, hMG was administered 3 ampules/day beginning cycle Day 3 and continued for at least 6 days. Estradiol and ultrasound evaluations were performed on Day 3, and then daily, beginning on cycle Day 8. Fourteen women completed all three cycles. There were no significant differences in baseline estradiol and ultrasound. Estradiol levels on Day 8 (A1, 754 ± 130; A2, 700 ± 107; B, 520 ± 80 pg/ml, analysis of variance p > 0.5) and on Day 9 (A1, 1051 ±144; A2, 1140 ± 155; B, 840 ± 124 pg/ml, p > 0.05) were similar as well. The number of small (1.0-1.4 cm) follicles, large (± 1.5 cm) follicles, and total follicles (Day 8: total A1, 5.5 ± 0.9; A2, 4.0 ± 0.7; B, 4.5 ± 0.9, p > 0.05; Day 9: total A1, 6.7 ± 0.9; A2, 6.9 ± 0.8; B, 6.9 ± 0.9, p > 0.05) in all three cycles were also similar. There was no significant difference in the day of hCG administration (A1, 9.1 ± 0.2; A2, 9.0 ± 0.1; B, 9.2 ± 0.2) or the total number of ampules of hMG utilized on Day 9 (A1, 1.1 ± 0.4; A2, 0.6 ± 0.2; B, 0.8 ±0.2). This study extends our previous observations in ovulatory women that ovarian response to hMG induction of superovulation is similar in successive cycles and demonstrates in vivo consistency of human ovarian response to different lots of Pergonal±

Original languageEnglish (US)
Pages (from-to)135-139
Number of pages5
JournalGynecological Endocrinology
Volume6
Issue number2
DOIs
StatePublished - Jan 1 1992

Fingerprint

Menotropins
varespladib methyl
Estradiol
Superovulation
Analysis of Variance

Keywords

  • Bioequivalence
  • Follicles
  • Human Menopausal Gonadotropin
  • Oocytes
  • Ovulation Induction

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Obstetrics and Gynecology

Cite this

Comparison of ovarian response in the same women with the same or different lots of human menopausal gonadotropin. / Diamond, M. P.; Polar, M. L.; Blanchette, M.; Mazure, C. M.; Dechemey, A. H.; Lunenfeld, B.

In: Gynecological Endocrinology, Vol. 6, No. 2, 01.01.1992, p. 135-139.

Research output: Contribution to journalArticle

Diamond, M. P. ; Polar, M. L. ; Blanchette, M. ; Mazure, C. M. ; Dechemey, A. H. ; Lunenfeld, B. / Comparison of ovarian response in the same women with the same or different lots of human menopausal gonadotropin. In: Gynecological Endocrinology. 1992 ; Vol. 6, No. 2. pp. 135-139.
@article{e6ad4bdc51b147b38d098e1030e39e7a,
title = "Comparison of ovarian response in the same women with the same or different lots of human menopausal gonadotropin",
abstract = "A variation in the bioactivity of different production lots of human menopausal gonadotropin (hMG) has been suggested. Therefore, we evaluated ovarian response to hMG in 14 women during three separate IVF cycles. The first two cycles were performed with the same lot (-03310027; Cycles A1 and A2); the third cycle utilized different lots of hMG (Cycle B). In all cycles, hMG was administered 3 ampules/day beginning cycle Day 3 and continued for at least 6 days. Estradiol and ultrasound evaluations were performed on Day 3, and then daily, beginning on cycle Day 8. Fourteen women completed all three cycles. There were no significant differences in baseline estradiol and ultrasound. Estradiol levels on Day 8 (A1, 754 ± 130; A2, 700 ± 107; B, 520 ± 80 pg/ml, analysis of variance p > 0.5) and on Day 9 (A1, 1051 ±144; A2, 1140 ± 155; B, 840 ± 124 pg/ml, p > 0.05) were similar as well. The number of small (1.0-1.4 cm) follicles, large (± 1.5 cm) follicles, and total follicles (Day 8: total A1, 5.5 ± 0.9; A2, 4.0 ± 0.7; B, 4.5 ± 0.9, p > 0.05; Day 9: total A1, 6.7 ± 0.9; A2, 6.9 ± 0.8; B, 6.9 ± 0.9, p > 0.05) in all three cycles were also similar. There was no significant difference in the day of hCG administration (A1, 9.1 ± 0.2; A2, 9.0 ± 0.1; B, 9.2 ± 0.2) or the total number of ampules of hMG utilized on Day 9 (A1, 1.1 ± 0.4; A2, 0.6 ± 0.2; B, 0.8 ±0.2). This study extends our previous observations in ovulatory women that ovarian response to hMG induction of superovulation is similar in successive cycles and demonstrates in vivo consistency of human ovarian response to different lots of Pergonal±",
keywords = "Bioequivalence, Follicles, Human Menopausal Gonadotropin, Oocytes, Ovulation Induction",
author = "Diamond, {M. P.} and Polar, {M. L.} and M. Blanchette and Mazure, {C. M.} and Dechemey, {A. H.} and B. Lunenfeld",
year = "1992",
month = "1",
day = "1",
doi = "10.3109/09513599209046397",
language = "English (US)",
volume = "6",
pages = "135--139",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Comparison of ovarian response in the same women with the same or different lots of human menopausal gonadotropin

AU - Diamond, M. P.

AU - Polar, M. L.

AU - Blanchette, M.

AU - Mazure, C. M.

AU - Dechemey, A. H.

AU - Lunenfeld, B.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - A variation in the bioactivity of different production lots of human menopausal gonadotropin (hMG) has been suggested. Therefore, we evaluated ovarian response to hMG in 14 women during three separate IVF cycles. The first two cycles were performed with the same lot (-03310027; Cycles A1 and A2); the third cycle utilized different lots of hMG (Cycle B). In all cycles, hMG was administered 3 ampules/day beginning cycle Day 3 and continued for at least 6 days. Estradiol and ultrasound evaluations were performed on Day 3, and then daily, beginning on cycle Day 8. Fourteen women completed all three cycles. There were no significant differences in baseline estradiol and ultrasound. Estradiol levels on Day 8 (A1, 754 ± 130; A2, 700 ± 107; B, 520 ± 80 pg/ml, analysis of variance p > 0.5) and on Day 9 (A1, 1051 ±144; A2, 1140 ± 155; B, 840 ± 124 pg/ml, p > 0.05) were similar as well. The number of small (1.0-1.4 cm) follicles, large (± 1.5 cm) follicles, and total follicles (Day 8: total A1, 5.5 ± 0.9; A2, 4.0 ± 0.7; B, 4.5 ± 0.9, p > 0.05; Day 9: total A1, 6.7 ± 0.9; A2, 6.9 ± 0.8; B, 6.9 ± 0.9, p > 0.05) in all three cycles were also similar. There was no significant difference in the day of hCG administration (A1, 9.1 ± 0.2; A2, 9.0 ± 0.1; B, 9.2 ± 0.2) or the total number of ampules of hMG utilized on Day 9 (A1, 1.1 ± 0.4; A2, 0.6 ± 0.2; B, 0.8 ±0.2). This study extends our previous observations in ovulatory women that ovarian response to hMG induction of superovulation is similar in successive cycles and demonstrates in vivo consistency of human ovarian response to different lots of Pergonal±

AB - A variation in the bioactivity of different production lots of human menopausal gonadotropin (hMG) has been suggested. Therefore, we evaluated ovarian response to hMG in 14 women during three separate IVF cycles. The first two cycles were performed with the same lot (-03310027; Cycles A1 and A2); the third cycle utilized different lots of hMG (Cycle B). In all cycles, hMG was administered 3 ampules/day beginning cycle Day 3 and continued for at least 6 days. Estradiol and ultrasound evaluations were performed on Day 3, and then daily, beginning on cycle Day 8. Fourteen women completed all three cycles. There were no significant differences in baseline estradiol and ultrasound. Estradiol levels on Day 8 (A1, 754 ± 130; A2, 700 ± 107; B, 520 ± 80 pg/ml, analysis of variance p > 0.5) and on Day 9 (A1, 1051 ±144; A2, 1140 ± 155; B, 840 ± 124 pg/ml, p > 0.05) were similar as well. The number of small (1.0-1.4 cm) follicles, large (± 1.5 cm) follicles, and total follicles (Day 8: total A1, 5.5 ± 0.9; A2, 4.0 ± 0.7; B, 4.5 ± 0.9, p > 0.05; Day 9: total A1, 6.7 ± 0.9; A2, 6.9 ± 0.8; B, 6.9 ± 0.9, p > 0.05) in all three cycles were also similar. There was no significant difference in the day of hCG administration (A1, 9.1 ± 0.2; A2, 9.0 ± 0.1; B, 9.2 ± 0.2) or the total number of ampules of hMG utilized on Day 9 (A1, 1.1 ± 0.4; A2, 0.6 ± 0.2; B, 0.8 ±0.2). This study extends our previous observations in ovulatory women that ovarian response to hMG induction of superovulation is similar in successive cycles and demonstrates in vivo consistency of human ovarian response to different lots of Pergonal±

KW - Bioequivalence

KW - Follicles

KW - Human Menopausal Gonadotropin

KW - Oocytes

KW - Ovulation Induction

UR - http://www.scopus.com/inward/record.url?scp=0026773634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026773634&partnerID=8YFLogxK

U2 - 10.3109/09513599209046397

DO - 10.3109/09513599209046397

M3 - Article

C2 - 1502931

AN - SCOPUS:0026773634

VL - 6

SP - 135

EP - 139

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 2

ER -